Growth hormone-releasing hormone induced transactivation of epidermal growth factor receptor in human triple-negative breast cancer cells

Autor: Eva Vacas, María J. Carmena, Andrew V. Schally, Ana M. Bajo, Laura Muñoz-Moreno, Pedro L. Valenzuela, Juan C. Prieto

Publikováno v: Peptides. 86:153-161

Triple-negative breast cancer (TNBC) is a subset of breast cancers which is negative for expression of estrogen and progesterone receptors and human epidermal growth factor receptor-2 (HER2). Chemotherapy is currently the only form of treatment for w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fde14fa12e4ecf0572422ca0e322b8a6
https://doi.org/10.1016/j.peptides.2016.11.004

Anti-proliferative and pro-apoptotic effects of GHRH antagonists in prostate cancer

Autor: Ana M. Bajo, Laura Muñoz-Moreno, María I. Arenas, Andrew V. Schally, Juan C. Prieto, Manuel Sánchez-Chapado, María J. Carmena

Publikováno v: Oncotarget
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid

Growth hormone-releasing hormone (GHRH) and its receptors have been implicated in the progression of various tumors. In vitro and in vivo studies have demonstrated that GHRH antagonists inhibit the growth of several cancers. GHRH antagonists, JMR-132

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28aee1a0430ca1e424b196853895f0c1
http://europepmc.org/articles/PMC5239544

Signalling pathways involved in antitumoral effects of VIP in human renal cell carcinoma A498 cells: VIP induction of p53 expression

Autor: Eva Vacas, Laura Muñoz-Moreno, Manuel Sánchez-Chapado, Ana B. Fernández-Martínez, Ana M. Bajo, Juan C. Prieto, María J. Carmena

Publikováno v: The International Journal of Biochemistry & Cell Biology. 53:295-301

Vasoactive intestinal peptide (VIP) decreases cell proliferation through PI3K signalling and prevents tumour progression in clear renal cell carcinoma (RCC). Here we analyzed the signalling pathways that mediate such VIP effects by using human RCC A4

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::573a74460aebd7cf6407a16a887f6f03
https://doi.org/10.1016/j.biocel.2014.05.036

Inhibitory effects of antagonists of growth hormone-releasing hormone on growth and invasiveness of PC3 human prostate cancer

Autor: M. Isabel Arenas, Ana B. Fernández-Martínez, Juan C. Prieto, Eva Vacas, María J. Carmena, Laura Muñoz-Moreno, Ana M. Bajo, Andrew V. Schally, Marta González-Santander, Elías Zarka

Publikováno v: International Journal of Cancer. 132:755-765

New approaches are needed to the therapy of advanced prostate cancer. This study determined the effect of growth hormone-releasing hormone (GHRH) antagonists, JMR-132 and JV-1-38 on growth of PC3 tumors as well as on angiogenesis and metastasis throu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa6104bc27ffb4cb8261209e0b1d892c
https://doi.org/10.1002/ijc.27716

Vasoactive intestinal peptide (VIP) induces malignant transformation of the human prostate epithelial cell line RWPE-1

Autor: María J. Carmena, Juan C. Prieto, M. Isabel Arenas, Manuel Sánchez-Chapado, Ana M. Bajo, Ana B. Fernández-Martínez

Publikováno v: Cancer Letters. 299:11-21

The carcinogenic potential of vasoactive intestinal peptide (VIP) was analyzed in non-tumor human prostate epithelial cells (RWPE-1) and in vivo xenografts. VIP induced morphological changes and a migratory phenotype consistent with stimulation of ex

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee08e99e2be43d9ba81a7f4c20843982
https://doi.org/10.1016/j.canlet.2010.07.019